Statement of Ownership (sc 13g)
April 01 2022 - 4:34PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. __)
Outlook Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
69012T 206
(CUSIP Number)
March 18, 2022
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:
☐
Rule 13d-1(b)
☒
Rule 13d-1(c)
☐
Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 69012T 206 |
Page 1 of 4 Pages |
1 |
NAME OF REPORTING PERSONS
Jason Hope |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨
(b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
USA |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER
15,012,357 shares of Common Stock |
6 |
SHARED VOTING POWER
0 |
7 |
SOLE DISPOSITIVE POWER
15,012,357 shares of Common Stock |
8 |
SHARED DISPOSITIVE POWER
0 |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
15,012,357 shares of Common Stock |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.69% |
12 |
TYPE OF REPORTING PERSON
IN |
|
|
|
|
CUSIP No. 69012T 206 |
Page 2 of 4 Pages |
Item 1(a). Name of Issuer:
Outlook Therapeutics, Inc.
Item 1(b). Address of Issuer’s Principal Executive Office:
485 Route 1 South
Building F, Suite 320
Iselin, New Jersey 08830
Item 2(a). Name of Person Filing:
Jason Hope
Item 2(B). Address of Principal Business Office or, if None,
Residence:
7150 E. Camelback Road #444
Scottsdale, Arizona 85251
Item 2(c). Citizenship:
United States of America
Item 2(d). Title of Class of Securities:
Common Stock
Item 2(e). CUSIP Number:
69012T 206
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b),
or 240.13d-2(b) or (c), check whether the person filing is a:
(a) ☐
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
(b) ☐
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) ☐
Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ☐
Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e) ☐
An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
(f) ☐
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) ☐
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) ☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
CUSIP No. 69012T 206 |
Page 3 of 4 Pages |
(i) ☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3);
(j) ☐
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) ☐
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
If filing as a non-U.S. institution in accordance
with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
Item 4. Ownership:
Provide the following information regarding
the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: 15,012,357 shares
of Common Stock
(b) Percent of class: 6.69%
(c) Number of shares as to which the person
has:
(i) Sole power to vote or direct the vote: 15,012,357
shares of Common Stock
(ii) Shared power to vote or direct the vote:
0
(iii) Sole power to dispose or to direct the disposition
of: 15,012,357 shares of Common Stock
(iv) Shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent of Less of a Class.
If this statement is being filed to report the
fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities,
check the following: ☐
Item 6. Ownership of More than 5 Percent on Behalf of Another
Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of a Group.
Not applicable.
CUSIP No. 69012T 206 |
Page 4 of 4 Pages |
Item 10. Certifications.
By signing below I certify that, to the best
of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §
240.14a-11.
SIGNATURES
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
April 1, 2022 |
|
(Date) |
|
|
|
/s/ Jason Hope |
|
(Signature) |
|
|
|
Jason Hope |
|
(Name and Title) |
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2024 to May 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From May 2023 to May 2024